Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study.

Background: Since the pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become the leading trigger for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Evidence indicates that autoimmunity plays an important pathophysiological role. We aimed to evaluate the effectiveness of IA treatment in post-COVID ME/CFS patients.
Methods: This pre-post study included 20 post-coronavirus disease 2019 (COVID) ME/CFS patients found to have elevated β2 adrenergic autoantibodies (β2 AR-AB) between October 2022 and October 2023. Patients, with a median disease duration of 22 months (IQR: 15-31), were treated with five immunoadsorption sessions at Charité - Universitätsmedizin Berlin, Germany. Seven were male and 13 female, with a median age of 40 years (IQR: 36-51). The primary end point was the change in the Short Form (36) Health Survey physical functioning domain (SF36 PF) from baseline to four weeks post immunoadsorption. Key symptoms were assessed via questionnaires over six months. Handgrip strength and EndoPAT® measurements were used to evaluate muscle fatigue and vascular dysfunction. Seven patients who worsened after an initial response received a second cycle.
Findings: The treatment was generally well tolerated, reducing total immunoglobulin G by 79% ( CI : 73-84%) and β2 AR-AB by 77% ( CI : 58-95%). Patients demonstrated a mean increase in the SF36 PF of 17.75 points ( CI : 13.41-26.16), with the greatest improvement occurring between months two and three, and significant gains maintained through month six. 14/20 (70%) patients were categorized as responders with an increase in the SF36 PF of ≥ ten points. Further lasting improvements were reported in fatigue, post-exertional malaise, pain, cognitive, autonomic, and immunological symptoms. Female patients had increased repeat handgrip strength at month six.
Interpretation: Immunoadsorption may improve symptoms in post-COVID ME/CFS patients. The beneficial effects of IgG depletion suggest a significant role for autoantibodies and disturbed B-cell function in the condition's pathophysiology.
Funding: Funded by The Federal Ministry of Education and Research and the Weidenhammer Zöbele Research Foundation.
Competing Interests: Charité holds, together with CellTrend, a patent for the diagnostic use of autoantibodies against β2 AR-AB. CS has a consulting agreement with CellTrend and Berlin Cures. MT has received grants from the DFG, BMBF, Weidenhammer Zöbele Stiftung, Baxter, and Cytosorbents. MT has a consulting agreement with AstraZeneca and has received honoraria for lectures from Aey-Congress, AstraZeneca, Boehringer Ingelheim, Bayer, Baxter, Cytosorbents, DGK, DHL, Fresenius, Medical Tribune, MedPoint, Novartis, Pfizer, Sanofi, and Vifor. MT has also received support for attending meetings from AstraZeneca and Vifor. Additionally, MT serves on data safety monitoring or advisory boards for AstraZeneca, Boehringer Ingelheim, and Takeda. PG has received honoraria for lectures and travel support from Miltenyi Biotec GmbH. The other authors declare no conflict of interest.
(© 2024 The Author(s).)